Spots Global Cancer Trial Database for pik3ca mutation
Every month we try and update this database with for pik3ca mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04524000 | Advanced Breast... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Treatment of Colon Cancer | NCT01108107 | Colon Cancer | Oxaliplatin Capecitabine Oxaliplatin Capecitabine Panitumumab | 18 Years - | Vejle Hospital | |
| A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | NCT01708161 | PIK3CA Mutated ... PIK3CA Amplifie... | BYL719 AMG 479 | 18 Years - | Novartis | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | NCT05759949 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... Hormone Recepto... | RLY-5836 Fulvestrant Palbociclib Ribociclib Abemaciclib | 18 Years - | Relay Therapeutics, Inc. | |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
| Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | NCT05472220 | Solid Tumors, A... PIK3CA Mutation... PIK3CA Mutation Human Papilloma... HPV-Related Squ... Human Papilloma... Locally Advance... Metastatic Mali... | Alpelisib Carboplatin Hyperpolarized ... Continuous Gluc... | 18 Years - | University of California, San Francisco | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | NCT05759949 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... Hormone Recepto... | RLY-5836 Fulvestrant Palbociclib Ribociclib Abemaciclib | 18 Years - | Relay Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
